Management of Hyperuricemia

Indications for Treatment

Serum uric acid levels >9 mg/dL are specifically identified in guidelines as indicating higher likelihood of gout progression and development of clinical tophi, warranting treatment even after a first gout flare 1, 3
The American College of Rheumatology (ACR) conditionally recommends initiating urate-lowering therapy (ULT) for patients experiencing their first flare when serum urate concentration >9 mg/dL 1, 2

Start allopurinol at a low dose (100 mg daily) and increase by 100 mg every two to four weeks until the target serum uric acid level is achieved 4, 5
The therapeutic goal is to maintain serum uric acid below 6 mg/dL, which is below the saturation point for monosodium urate (360 μmol/L) 4, 5
Every 100 mg increment of allopurinol reduces serum uric acid by approximately 1 mg/dL (60 μmol/L) 4, 5

Regular monitoring of serum uric acid levels is necessary to guide dose titration 2
Consider anti-inflammatory prophylaxis when initiating ULT to prevent acute gout flares 2

While the FDA label states that allopurinol is "not recommended for the treatment of asymptomatic hyperuricemia," this refers to mild-moderate elevations; levels >9 mg/dL represent a special case where treatment is justified 1, 3
Potential adverse effects include skin reactions, which occur in a small percentage of patients 6
Allopurinol requires dose adjustment when used concomitantly with certain medications, including 6-mercaptopurine, azathioprine, and certain cytotoxic agents 6, 7
The "go low, go slow" strategy of starting at 100 mg daily and gradually increasing the dose reduces the likelihood of provoking acute gout attacks during initiation 4, 5